Stock Scorecard
Stock Summary for CRISPR Therapeutics AG (CRSP) - $56.30 as of 9/4/2026 7:31:03 PM EST
Total Score
5 out of 30
Safety Score
40 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CRSP
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CRSP
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CRSP
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CRSP
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CRSP (40 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CRSP
Financial Details for CRSP
Company Overview |
|
|---|---|
| Ticker | CRSP |
| Company Name | CRISPR Therapeutics AG |
| Country | N/A |
| Description | CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 56.30 |
| Price 4 Years Ago | 40.65 |
| Last Day Price Updated | 9/4/2026 7:31:03 PM EST |
| Last Day Volume | 1,491,345 |
| Average Daily Volume | 1,472,978 |
| 52-Week High | 78.48 |
| 52-Week Low | 44.12 |
| Last Price to 52 Week Low | 27.61% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.24 |
| Sector PE | 46.81 |
| 5-Year Average PE | -16.01 |
| Free Cash Flow Ratio | 18.70 |
| Industry Free Cash Flow Ratio | 32.65 |
| Sector Free Cash Flow Ratio | 32.82 |
| Current Ratio Most Recent Quarter | 17.85 |
| Total Cash Per Share | 3.01 |
| Book Value Per Share Most Recent Quarter | 18.07 |
| Price to Book Ratio | 3.29 |
| Industry Price to Book Ratio | 5.58 |
| Sector Price to Book Ratio | 9.15 |
| Price to Sales Ratio Twelve Trailing Months | 410.25 |
| Industry Price to Sales Ratio Twelve Trailing Months | 39.34 |
| Sector Price to Sales Ratio Twelve Trailing Months | 13.00 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 96,693,000 |
| Market Capitalization | 5,443,815,900 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -58.80% |
| Reported EPS 12 Trailing Months | -4.71 |
| Reported EPS Past Year | -2.22 |
| Reported EPS Prior Year | -5.41 |
| Net Income Twelve Trailing Months | -451,139,000 |
| Net Income Past Year | -581,599,000 |
| Net Income Prior Year | -366,252,000 |
| Quarterly Revenue Growth YOY | 1,041.00% |
| 5-Year Revenue Growth | 37.31% |
| Operating Margin Twelve Trailing Months | -1,128.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 291,337,000 |
| Total Cash Past Year | 355,188,000 |
| Total Cash Prior Year | 298,257,000 |
| Net Cash Position Most Recent Quarter | -294,861,000 |
| Net Cash Position Past Year | 355,188,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 586,198,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.75 |
| Total Stockholder Equity Past Year | 1,921,813,000 |
| Total Stockholder Equity Prior Year | 1,932,080,000 |
| Total Stockholder Equity Most Recent Quarter | 1,746,551,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -480,726,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -4.97 |
| Free Cash Flow Past Year | -345,928,000 |
| Free Cash Flow Prior Year | -144,675,000 |
Options |
|
| Put/Call Ratio | 0.37 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.74 |
| RSI | 0.00 |
| 50-Day SMA | 54.84 |
| 150-Day SMA | 53.27 |
| 200-Day SMA | 52.92 |
System |
|
| Modified | 9/3/2026 9:05:32 PM EST |